Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Volitionrx (VNRX) Liabilities and Shareholders Equity (2019 - 2025)

Volitionrx (VNRX) has disclosed Liabilities and Shareholders Equity for 9 consecutive years, with $6.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 49.14% year-over-year to $6.4 million, compared with a TTM value of $33.1 million through Sep 2025, down 54.78%, and an annual FY2024 reading of $9.4 million, down 66.37% over the prior year.
  • Liabilities and Shareholders Equity was $6.4 million for Q3 2025 at Volitionrx, down from $8.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $35.2 million in Q2 2021 and bottomed at $6.4 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $20.0 million, with a median of $18.9 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity soared 52.78% in 2023, then plummeted 66.37% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $27.5 million in 2021, then plummeted by 33.45% to $18.3 million in 2022, then skyrocketed by 52.78% to $28.0 million in 2023, then plummeted by 66.37% to $9.4 million in 2024, then tumbled by 31.39% to $6.4 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for VNRX at $6.4 million in Q3 2025, $8.7 million in Q2 2025, and $8.5 million in Q1 2025.